Home / Peptides

Octreotide

Shop Octreotide
Code ths10 applied at checkout
By The Health Stacks Research TeamUpdated September 7, 2026

Octreotide is a man-made medicine that acts like a hormone found naturally in the body. It is used by doctors to treat specific health problems, mostly those involving growth issues or tumors. This drug is a type of peptide, which is a small chain of amino acids. It is often given to patients with acromegaly, a condition where the body makes too much growth hormone. It is also used for certain tumors in the stomach and intestines. Doctors prescribe this medicine to help control serious symptoms and stop tumors from growing.

This medicine works by copying the action of a natural hormone called somatostatin. It helps to slow down the body's production of certain hormones and fluids. In people with acromegaly, it lowers the amount of growth hormone in the blood to normal levels. For those with tumors, it helps stop the release of chemicals that cause pain and flushing. It is very good at managing the severe diarrhea caused by some types of cancer. By blocking these actions, it helps patients feel much better and prevents long-term damage to the body.

The use of this medicine is well-studied, but it must be given by a shot under the skin or into a muscle. There are different forms, including some that last a long time in the body. While it helps many people, it can cause side effects like gallstones or tummy pain. Some patients may need to switch medicines if the first one does not work well or causes bad reactions. It is a strong drug that requires careful watching by a doctor to make sure it is working right.

ApprovedApproved by a regulator (e.g. FDA) for a specific medical use — the highest research-status tier. High confidence60–79 — backed by solid sources with good corroboration across multiple citations.

Benefits

What Octreotide Helps With

The benefits people report — backed by research.

Reproductive & hormonal (23)

Pegvisomant blocks growth hormone receptors and reduces IGF-1 levels 72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 3 srcDopamine agonists lower GH levels in acromegaly 72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 3 srcSomatostatin analogues inhibit GH secretion from pituitary tumours 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcPegvisomant blocks the growth hormone receptor, reducing IGF-1 levels 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcIntramuscular injections of somatostatin analogues are generally more effective than oral dopamine agonists in lowering GH levels 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcIntramuscular injections of somatostatin analogues are more effective than oral tablets for acromegaly 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcPegvisomant blocks the growth hormone receptor, reducing IGF-1 levels in acromegaly 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 2 srcSuppresses growth hormone secretion 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Controls biochemical parameters of acromegaly in 60 to 80% of patients 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Somatostatin analogues reduce growth hormone release and control pituitary tumour size in gigantism 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Pegvisomant blocks growth hormone from exerting effects on the body 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Dopaminergic tablets lower growth hormone levels 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Somatostatin analogues inhibit GH secretion from pituitary tumours in acromegaly 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Dopamine agonists lower GH levels 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Pegvisomant blocks the growth hormone receptor, reducing IGF-1 levels in acromegaly patients 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Dopamine agonists lower GH levels orally in acromegaly 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Maintenance of biochemical control in acromegaly 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Profound suppression of growth hormone levels 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Significant reduction in acromegaly related symptoms 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Somatostatin analogue use decreases mortality risk in acromegaly 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Pegvisomant normalizes IGF-1 in patients resistant to somatostatin analogues 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Cabergoline effective in combination with somatostatin analogues for IGF-1 normalization 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Block the growth hormone secretagogue receptor 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Cancer / tumor (14)

Octreotide decreases the incidence of pancreatic cancer and metastatic disease 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →COX-2 inhibitor reduces pancreatic cancer and prevents intraductal papillary carcinoma 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →COX-2 inhibitor reduces pancreatic cancer incidence and prevents intraductal papillary carcinoma 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Propranolol demonstrates a cancer-protective effect against PDAC 80/100Rated 80/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Significant increase in objective response rate in epNETs 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treatment of carcinoid crisis 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Somatostatin analogues reduce hormone production and may slow tumour growth in carcinoid tumours 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Peptide receptor radionuclide therapy uses a radioactive substance attached to a peptide to target carcinoid tumour cells 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Octreotide LAR provides biochemical control and tumor size reduction 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Slowing tumor growth in widespread medullary thyroid cancer 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Somatostatin analogues stabilise non-functioning pancreatic NET disease 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Everolimus and Sunitinib improve outcomes in advanced non-functioning pancreatic NETs 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Peptide receptor radionuclide therapy for progressive pancreatic NETs 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Suppresses ACTH secretion from pituitary corticotroph tumors 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Gastrointestinal & gut (10)

Stabilization of metastatic gastrinoma disease progression 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Metformin inhibits small intestinal neuroendocrine tumor growth in vivo 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Somatostatin analogues stabilize metastatic gastrinoma disease 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Gastric / gut lining 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Insulin sensitivity 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reduces splanchnic blood flow, GI motility, and exocrine pancreatic secretion 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Stimulating chloride and bicarbonate secretion 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Preventing zonulin-mediated opening of tight junctions 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Prevent gluten peptide translocation across the intestinal barrier 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Regulates chloride and bicarbonate secretion into the intestinal lumen 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Neuroprotection & cognitive (7)

Significant improvement in BICR-assessed progression-free survival for advanced extrapancreatic neuroendocrine tumors 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Improvement in quality of life and reduction of anxiety and depression symptoms with scalp hair regrowth in severe alopecia areata 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →[¹⁸F]AlF-NOTA-octreotide PET/CT effective for routine clinical evaluation in neuroendocrine tumor patients 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Relief of MTC symptoms 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Brain / cognitive 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Antiproliferative effects on neuroendocrine tumor cells 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Reducing visceral pain signaling 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Glycemic & metabolic (5)

Brain / cognitive 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Octreotide and lanreotide therapy improves lipid profile 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Somatostatin analogues control low blood glucose symptoms 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Insulin sensitivity 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Block the glucagon receptor and prevent glucagon-mediated hepatic glucose output 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

More reported benefits (10)

Somatostatin analogues inhibit GH secretion from pituitary tumours in acromegaly 72/100Rated 72/100Source typeEstablished referenceIndependent sources5Every claim links to the page it came from, and stronger sources rate higher. Full methodology →· 5 srcSymptomatic treatment of amine secretion 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Stimulate gallbladder contraction, pancreatic enzyme secretion, and satiety signaling 60/100Rated 60/100Source typeSpecialist communityIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Skin health 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Symptom relief and ulcer healing via acid suppression 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Lack of injection-related side effects 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →CGRP monoclonal antibodies show efficacy and safety in chronic migraine 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Disease control improves joint articular cartilage thickness and reduces vertebral fractures 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Treatment with somatostatin analogues improves left ventricular function and decreases arrhythmias 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →Achieving disease control reduces total direct treatment costs compared to uncontrolled disease 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →

Free: The Peptide Stack Cheat-Sheet

You just read the research on Octreotide. The cheat-sheet maps the most-used peptide stacks — doses, timing, and what to check before buying — on one page.

No spam. Unsubscribe anytime.

How People Use It

1 reported routine — each line links to the source it came from.

From published sources

Routines as reported in peer-reviewed papers, clinical guidance, or vetted media — each linked to the source it came from.

SubQ

  • 40 mg to 80 mg daily (20 mg twice daily) 95/100Rated 95/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source

mg vs mcg: one milligram (mg) equals 1,000 micrograms (mcg) — multiply by 1,000 going from mg to mcg, divide by 1,000 going from mcg to mg. Mixing the two up is a thousand-fold dosing error: 1 mg taken instead of 1 mcg is a 1,000× overdose; 1 mcg instead of 1 mg is a 1,000× underdose. Always double-check the unit label and the decimal place.

Safety

Known Side Effects

Adverse effects reported in the research and by community use.

  • AnorexiaSevereReported in 2 sources 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pancreapedia.org↗ pancreapedia.org
  • Severe abdominal painSevere 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pancreapedia.org
  • weight lossSevere 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pancreapedia.org
  • and diarrhea requiring euthanasiaSevere 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pancreapedia.org
  • jaundiceSevere 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pancreapedia.org
  • ascitesSevere 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pancreapedia.org
  • and cachexia in pancreatic cancer patientsSevere 85/100Rated 85/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ pancreapedia.org
  • Octreotide-associated gallbladder stonesModerate 75/100Rated 75/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ doi.org
  • Hypertension (Grade ≥ 3 treatment-related adverse event)Severe 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medscape.com
  • Diarrhea (Grade ≥ 3 treatment-related adverse event)Severe 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ medscape.com
  • Cutaneous flushingModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ dermnetnz.org
  • Carcinoid crisis (hypotensionLifeThreatening 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ dermnetnz.org
  • Carcinoid heart disease (valve fibrosis)Severe 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ dermnetnz.org
  • Pellagra (dermatitisModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ dermnetnz.org
  • HyperglycemiaModerateReported in 7 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources7Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ link.springer.com↗ e-enm.org↗ snbiopharm.com↗ snbiopharm.com+3
  • Somatostatin analogue-induced stomach upset and diarrhoeaMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Somatostatin analogue-induced gallstonesModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Dopamine agonist-induced nausea and vomitingMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Dopamine agonist-induced mood changes and dizzinessMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Pegvisomant-induced liver function disturbanceModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Somatostatin analogue adverse events: stomach upsetsMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Dopaminergic adverse events: loss of appetiteMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Pegvisomant adverse events: liver function disturbanceModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Pituitary surgery complications: excessive bleedingModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Radiotherapy short-term side-effects: blurred visionMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • NauseaModerateReported in 5 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources5Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info↗ snbiopharm.com↗ snbiopharm.com↗ snbiopharm.com+1
  • DiarrhoeaModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Worsening of diabetes controlModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Gallstone formationModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Vitamin B12 deficiencyModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Low magnesium levelsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Increased risk of bone fracturesModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Bone marrow suppressionSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • AlopeciaModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Gastrointestinal disturbanceModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Bone marrow and kidney damageSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Discomfort and damage to surrounding healthy liver tissueModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Somatostatin analogues (OctreotideMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Dopamine agonists adverse effectsMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Pegvisomant liver function disturbanceModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info↗ yourhormones.info
  • Somatostatin analogue adverse effects: stomach upsetsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Dopamine agonist adverse effects: mood changes, loss of appetite, nausea, vomiting, dizzinessModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Pegvisomant adverse effect: disturbed liver functionModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Stomach upsets and diarrhoea from somatostatin analoguesMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Gallstones from somatostatin analoguesModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Mood changesMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Liver function disturbance from PegvisomantModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Somatostatin analogues causing stomach upsets and diarrhoeaMildReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info↗ yourhormones.info
  • Somatostatin analogues causing gallstonesModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info↗ yourhormones.info
  • Pegvisomant causing liver function disturbanceModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Somatostatin analogue adverse effects: stomach upsets and diarrhoeaMildReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info↗ yourhormones.info
  • Somatostatin analogue adverse effects: gallstones (rare)ModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info↗ yourhormones.info
  • Dopamine agonist adverse effects: mood changesMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Pegvisomant adverse effects: disturbed liver functionModerateReported in 2 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources2Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info↗ yourhormones.info
  • Somatostatin analogues (OctreotideModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Dopamine agonists (Cabergoline, Bromocriptine) adverse effects: mood changes, loss of appetite, nausea, vomiting, dizzinessMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Dopamine agonists causing nauseaMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Pegvisomant causing disturbed liver functionModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Nausea and diarrhoeaModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ link.springer.com
  • HeadacheMildReported in 5 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources5Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ link.springer.com↗ snbiopharm.com↗ snbiopharm.com↗ snbiopharm.com+1
  • ArthralgiaMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ link.springer.com
  • Bile stonesModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ link.springer.com
  • Hypopituitarism from radiotherapySevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ link.springer.com
  • Cerebrovascular events/stroke from radiotherapySevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ link.springer.com
  • Secondary brain tumors from radiotherapySevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ link.springer.com
  • Worsening glucose-related metabolic abnormalities from somatostatin therapyModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ link.springer.com
  • Increased risk of elevated liver transaminase levels (Pegvisomant)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ link.springer.com
  • Increased risk of cardiac valvular abnormalities (Cabergoline)Severe 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ link.springer.com
  • Somatostatin analogues GI effects (stomach upsetsMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Gallstones (rareModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Dopamine agonists CNS/GI effects (mood changes, loss of appetite, nausea, vomiting, dizziness)Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • DiarrheaModerateReported in 6 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources6Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info↗ yourhormones.info↗ snbiopharm.com↗ snbiopharm.com+2
  • Bone marrow and kidney effects (PRRT)Severe 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Dopaminergic adverse effects: loss of appetiteMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Pegvisomant adverse effects: liver function disturbanceModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Diazoxide side effectsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Surgery side effectsSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Hypocalcaemia (Post-parathyroid surgery)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Diabetes insipidus (Post-pituitary surgery)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Diabetes mellitus and digestive enzyme deficiency (Post-pancreatic surgery)Severe 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • GallstonesModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Stomach crampsMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Fatigue (from nuclear medicine treatments)Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Bone marrow suppression causing anemiaSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Kidney function damageSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Somatostatin analogue therapy adverse eventsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • PRRT therapy adverse eventsSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Surgery adverse eventsSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Chemotherapy adverse eventsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • tachycardia/arrhythmiasLifeThreatening 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ dermnetnz.org
  • bronchospasm)LifeThreatening 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ dermnetnz.org
  • dementiaModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ dermnetnz.org
  • diarrhoea)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ dermnetnz.org
  • diarrhoeaMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • gallstonesMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • nauseaMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • VomitingMildReported in 3 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources3Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info↗ snbiopharm.com↗ snbiopharm.com
  • DizzinessMildReported in 4 sources 72/100Rated 72/100Source typeEstablished referenceIndependent sources4Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info↗ snbiopharm.com↗ snbiopharm.com↗ snbiopharm.com
  • infectionModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • abnormal sodium levelsModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • headachesMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • lethargyMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • diarrhoeaModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • gallstonesModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • loss of appetiteMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • nauseaMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • vomiting and dizziness from dopamine agonistsMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • loss of appetiteMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • nauseaMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • vomiting and dizzinessMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • diarrhoeaModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • gallstonesModerate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • VomitingMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • and dizzinessMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • diarrhoea)Mild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • from somatostatin analogues)Moderate 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • nauseaMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • vomiting and dizzinessMild 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • low plateletsSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • and low white cell countSevere 72/100Rated 72/100Source typeEstablished referenceIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ yourhormones.info
  • Sandostatin (octreotide) impairs postresection intestinal adaptationModerate 70/100Rated 70/100Source typePeer-reviewed studyIndependent sources1Every claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ doi.org

Reported in research and community sources — not exhaustive. Discontinue use and consult a healthcare professional if side effects occur.

Get Octreotide

Compare research-grade suppliers with third-party COAs and published purity data. For in-vitro and laboratory research use only — not for human consumption, diagnosis, or treatment.

Shop Octreotide
Code ths10 applied at checkout

Evidence

Research Citations (2)

Every claim above traces back to a source you can check — here are 2 of them.

  • (177)Lu]Lu-DOTA-TATE plus long-acting octreotide versus high‑dose long-acting octreotide for the treatment of newly diagnosed, advanced grade 2-3, well-differentiated, gastroenteropancreatic neuroendocrine tumours (NETTER-2): an open-label, randomised, phase 3 study.

    2024 95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

  • Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study.

    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →
    Source

Timeline

History & Milestones

Key moments in Octreotide’s research and regulatory timeline — sourced and dated.

  1. Octreotide-SSTR5 complex structurePublicationDec 15, 1975
    Related:Octreotide
    95/100Rated 95/100Source typePeer-reviewed studyIndependent sourcesstill being verifiedEvery claim links to the page it came from, and stronger sources rate higher. Full methodology →↗ source

Wondering how Octreotide pricing compares across suppliers? Our original market data shows the full picture.

See the State of the Peptide Market 2026 →

Free: The Peptide Stack Cheat-Sheet

The most-used peptide combinations, what the research actually says, and where to buy — one page, one email.

No spam. Unsubscribe anytime.